FDA Issues Warning on Controversial MS
THURSDAY, May 10 (HealthDay News) -- Doctors and patients need
to be aware of the potential risk of injuries and death associated
with an experimental treatment for multiple sclerosis called
liberation therapy, the U.S. Food and Drug Administration said in
an alert issued Thursday.
Liberation therapy is used to treat chronic cerebrospinal venous
insufficiency (CCSVI) -- a narrowing of veins in the neck and chest
-- believed by some to cause multiple sclerosis (MS) or worsen the
disease. They think it does so by impairing blood drainage from the
brain and upper spinal cord.
The controversial procedure uses balloon angioplasty devices or
stents to widen narrowed veins in the chest and neck. But the FDA
has not approved this treatment for chronic cerebrospinal venous
insufficiency, and the agency said it has learned of deaths,
strokes, damage to the treated vein, blood clots, cranial nerve
damage, abdominal bleeding, and migration of stents in the body as
a result of the treatment.
Also, studies examining a possible link between the two
conditions are inconclusive, and the criteria used to diagnose
chronic cerebrospinal venous insufficiency have not been adequately
established, the FDA said.
"Because there is no reliable evidence from controlled clinical trials that this procedure is effective in treating MS, FDA encourages rigorously conducted, properly targeted research to evaluate the relationship between CCSVI and MS," Dr. William Maisel, chief scientist and deputy director for science in the FDA's Center for Devices and Radiological Health, said in an agency news release.
"Patients are encouraged to discuss the potential risks and benefits of this procedure with a neurologist or other physician who is familiar with MS and CCSVI, including the CCSVI procedures and their outcomes," he added.
One MS expert agreed with the FDA's warning, but said she
understood why some patients might be drawn to the therapy.
"MS patients have a progressive disease. The response by many is to seek out the newest potential treatment or 'cure,'" said Dr. Karen Blitz-Shabbir, director of the Multiple Sclerosis Center at North Shore-LIJ Health System in Manhasset, N.Y. "Whether CCSVI will even be helpful is still unknown. MS centers around the country are not recommending this treatment at this time because it is
unproven and may be dangerous," she added.
MS is a progressive autoimmune disease that affects the nervous
system. Its underlying cause is unknown.
The FDA said that it is also is notifying doctors and clinical
investigators who are planning or conducting clinical trials using
medical devices to treat chronic cerebrospinal venous insufficiency
that they must comply with FDA regulations for investigational
Dr. Fred Lublin, director of the Corinne Goldsmith Dickinson
Center for Multiple Sclerosis at Mount Sinai School of Medicine in
New York City, also welcomed the alert.
"The FDA's action is well-founded and provides an important safeguard for individuals with MS," he said.
"There are safety issues with the procedures associated with CCSVI, as detailed in the FDA alert," Lublin said. He also said the very existence of chronic cerebrospinal venous insufficiency is unclear. And, "whether there is any relationship between CCSVI and MS, as either a cause or consequence, is unproven," he added.
Without scientific studies supporting the treatment of chronic
cerebrospinal venous insufficiency in patients with MS, the
procedure cannot be recommended, Lublin said.
The American Academy of Family Physicians has more about
Copyright © 2012
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.